These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18007999)

  • 1. Meeting report: hazard assessment for nanoparticles--report from an interdisciplinary workshop.
    Balbus JM; Maynard AD; Colvin VL; Castranova V; Daston GP; Denison RA; Dreher KL; Goering PL; Goldberg AM; Kulinowski KM; Monteiro-Riviere NA; Oberdörster G; Omenn GS; Pinkerton KE; Ramos KS; Rest KM; Sass JB; Silbergeld EK; Wong BA
    Environ Health Perspect; 2007 Nov; 115(11):1654-9. PubMed ID: 18007999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop.
    Warheit DB; Borm PJ; Hennes C; Lademann J
    Inhal Toxicol; 2007 Jun; 19(8):631-43. PubMed ID: 17510836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research strategies for safety evaluation of nanomaterials, part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs.
    Holsapple MP; Farland WH; Landry TD; Monteiro-Riviere NA; Carter JM; Walker NJ; Thomas KV
    Toxicol Sci; 2005 Nov; 88(1):12-7. PubMed ID: 16120754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manufactured nanomaterials: categorization and approaches to hazard assessment.
    Gebel T; Foth H; Damm G; Freyberger A; Kramer PJ; Lilienblum W; Röhl C; Schupp T; Weiss C; Wollin KM; Hengstler JG
    Arch Toxicol; 2014 Dec; 88(12):2191-211. PubMed ID: 25326817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical hazard evaluation strategy for nanomedicines.
    Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
    Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk.
    Kavlock R; Dix D
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):197-217. PubMed ID: 20574897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in assessing nanomaterial toxicology: a personal perspective.
    Geraci CL; Castranova V
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(6):569-77. PubMed ID: 20799267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotoxicology for safe and sustainable nanotechnology.
    Drobne D
    Arh Hig Rada Toksikol; 2007 Dec; 58(4):471-8. PubMed ID: 18063532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecotoxicity test methods and environmental hazard assessment for engineered nanoparticles.
    Crane M; Handy RD; Garrod J; Owen R
    Ecotoxicology; 2008 Jul; 17(5):421-37. PubMed ID: 18438709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered nanoparticles and their identification among natural nanoparticles.
    Zänker H; Schierz A
    Annu Rev Anal Chem (Palo Alto Calif); 2012; 5():107-32. PubMed ID: 22482788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The uncertainty of nanotoxicology: report of a Society for Risk Analysis Workshop.
    Canady RA
    Risk Anal; 2010 Nov; 30(11):1663-70. PubMed ID: 21070298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of nanotoxicology: implications for drug delivery and medical devices.
    Bhattacharjee S; Brayden DJ
    Nanomedicine (Lond); 2015 Jul; 10(14):2289-305. PubMed ID: 26114880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing risk assessment of engineered nanomaterials: application of computational approaches.
    Gajewicz A; Rasulev B; Dinadayalane TC; Urbaszek P; Puzyn T; Leszczynska D; Leszczynski J
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1663-93. PubMed ID: 22664229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for nanoparticle surface reactivity in facilitating pulmonary toxicity and development of a base set of hazard assays as a component of nanoparticle risk management.
    Warheit DB; Reed KL; Sayes CM
    Inhal Toxicol; 2009 Jul; 21 Suppl 1():61-7. PubMed ID: 19558235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach to using mechanism-based structure activity relationship (SAR) analysis to assess human health hazard potential of nanomaterials.
    Lai DY
    Food Chem Toxicol; 2015 Nov; 85():120-6. PubMed ID: 26111809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles, human health hazard and regulation.
    Seaton A; Tran L; Aitken R; Donaldson K
    J R Soc Interface; 2010 Feb; 7 Suppl 1(Suppl 1):S119-29. PubMed ID: 19726441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotoxicity: hazard identification and risk assessment.
    Luster MI; Kimber I
    Hum Exp Toxicol; 1996 Dec; 15(12):947-8. PubMed ID: 8981097
    [No Abstract]   [Full Text] [Related]  

  • 18. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.
    Oberdörster G; Oberdörster E; Oberdörster J
    Environ Health Perspect; 2005 Jul; 113(7):823-39. PubMed ID: 16002369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the dawn of nanoecotoxicological research.
    Kahru A; Ivask A
    Acc Chem Res; 2013 Mar; 46(3):823-33. PubMed ID: 23148404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop.
    Bogdanffy MS; Daston G; Faustman EM; Kimmel CA; Kimmel GL; Seed J; Vu V
    Toxicol Sci; 2001 May; 61(1):18-31. PubMed ID: 11294970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.